Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coagadex Prophylaxis in Pediatric Factor X Deficiency
NCT01721681Phase 3Completed
- Sponsor
- Bio Products Laboratory
- Start
- Apr 2015
- Primary completion
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of coagulation factor X human in factor X deficiency (FXD), sponsored by Bio Products Laboratory. Primary endpoint: Number of Participants With Excellent Reduction in Bleeding at 6 months. Started Apr 2015; status: completed.
02
Drugs
coagulation factor X human
03
Conditions
factor X deficiency (FXD)
Beyond the preview
Go deeper on NCT01721681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01721681.